AN
ANL.US Adlai Nortye Ltd. American Depositary Shares
- Market cap
- USD 683M
- P/E
- -
- P/B
- 3.15x
- ROE
- -5.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ANL.US undervalued?
Graham numberThe Graham number of Adlai Nortye Ltd. American Depositary Shares cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Adlai Nortye Ltd. American Depositary Shares fundamental analysis
No fundamental analysis for Adlai Nortye Ltd. American Depositary Shares yet.
Adlai Nortye Ltd. American Depositary Shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a…
Full company profileAdlai Nortye Ltd. American Depositary Shares financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Adlai Nortye Ltd. American Depositary Shares annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | - | 45.7M | 0.00 | 5.00M | 0.00 | 5.00M | 29.4M |
| Gross Profit | -1.48M | -1.51M | 45.7M | -2.04M | 5.00M | -1.87M | 5.00M | 29.4M |
| Operating Income | -19.1M | -26.1M | -8.65M | -67.3M | -72.6M | -52.9M | -35.7M | -11.5M |
| EBITDA | -15.9M | -60.0M | -53.5M | -56.3M | -106M | -48.1M | -32.6M | -10.8M |
| Net Income | -17.8M | -63.4M | -56.7M | -58.8M | -109M | -51.9M | -35.5M | -10.7M |
| EPS | -2.10 | -7.47 | -4.61 | -4.78 | -16 | -4.87 | -3.33 | -0.67 |
| Balance Sheet | ||||||||
| Total Assets | 10.8M | 36.7M | 132M | 72.6M | 130M | 71.3M | 34.4M | 248M |
| Total Liabilities | 80.2M | 168M | 317M | 314M | 55.1M | 45.8M | 42.8M | 33.5M |
| Shareholders' Equity | -69.4M | -132M | -185M | -241M | 75.0M | 25.5M | -8.32M | 215M |
| Cash & Short-term Investments | 6.02M | 24.5M | 118M | 64.0M | 98.5M | 60.9M | 23.8M | 233M |
| Total Debt | 11.9M | 11.0M | 13.3M | 6.54M | 31.5M | 27.2M | 26.4M | 26.7M |
| Cash Flow | ||||||||
| Operating Cash Flow | -14.9M | -34.6M | -3.03M | -43.2M | -56.7M | -51.8M | -33.5M | -30.7M |
| Capital Expenditure | 185K | 1.62M | 1.12M | 1.27M | 200K | 170K | 187K | 374K |
| Free Cash Flow | -15.1M | -36.2M | -4.15M | -44.5M | -56.9M | -52.0M | -33.7M | -30.7M |
| Ratios | ||||||||
| ROE | - | - | - | - | -145.5% | -203.5% | - | -5.0% |
| ROA | -165.0% | -172.5% | -43.0% | -81.0% | -83.9% | -72.8% | -103.2% | -4.3% |
| Net Profit Margin | - | - | -124.0% | - | -2,186.5% | - | -710.6% | -36.3% |
| Debt to Equity | - | - | - | - | 0.42x | 1.07x | - | 0.12x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Adlai Nortye Ltd. American Depositary Shares dividends
Adlai Nortye Ltd. American Depositary Shares has not paid dividends in the last 7 fiscal years.
Who owns Adlai Nortye Ltd. American Depositary Shares
- Insiders 0.94%
- Institutions 41.94%
- Public & others 57.12%
- Shares outstanding 58.7M
- Free float 49.6M
Top funds holding ANL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Eventide Healthcare & Life Sciences I | 719K | 1.12% | 0.00% | Jun 2026 |
| Tema Oncology ETF | 103K | 0.16% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® EM Sm Cp ETF | 29.0K | 0.05% | 0.00% | Oct 2026 |
| Virtus Biotech Clinical Trials ETF | 25.9K | 0.04% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 17.0K | 0.03% | 0.00% | Aug 2026 |
| Telescope Biotech Fund A FIL | 8.95K | 0.01% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® China ETF | 7.20K | 0.01% | 0.00% | Oct 2026 |
| ActivePassive International Equity ETF | 4.23K | 0.01% | 0.00% | Oct 2026 |
| ProFunds UltraChina Inv | 1.16K | 0.00% | 0.00% | Jul 2026 |
Top institutions holding ANL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Cormorant Asset Management, LLC | 3.98M | 6.18% | +37.28% | Jun 2026 |
| VR Adviser, LLC | 3.21M | 4.99% | 0.00% | Jun 2026 |
| Balyasny Asset Management LLC | 3.06M | 4.75% | +248.77% | Jun 2026 |
| Point72 Asset Management, L.P. | 2.14M | 3.32% | 0.00% | Jun 2026 |
| MPM Oncology Impact Management LP | 1.94M | 3.01% | 0.00% | Jun 2026 |
| Perceptive Advisors LLC | 1.79M | 2.78% | 0.00% | Jun 2026 |
| Casdin Capital, LLC | 1.25M | 1.94% | +132.14% | Jun 2026 |
| ADAR1 Capital Management LLC | 1.02M | 1.58% | +763.21% | Jun 2026 |
| Octagon Capital Advisors LP | 935K | 1.45% | 0.00% | Jun 2026 |
| Millennium Management LLC | 808K | 1.25% | +18.49% | Jun 2026 |
| BRAIDWELL LP | 795K | 1.23% | 0.00% | Jun 2026 |
| Squadron Capital Management LLC | 765K | 1.19% | -39.55% | Jun 2026 |
| Eventide Asset Management, LLC | 719K | 1.12% | 0.00% | Jun 2026 |
| SUPERSTRING CAPITAL MANAGEMENT LP | 553K | 0.86% | +33.18% | Jun 2026 |
| Adage Capital Partners Gp LLC | 538K | 0.84% | 0.00% | Jun 2026 |
| Woodline Partners LP | 456K | 0.71% | +117.78% | Jun 2026 |
| Soleus Capital Management, L.P. | 406K | 0.63% | 0.00% | Jun 2026 |
| Freestone Grove Partners LP | 397K | 0.62% | 0.00% | Jun 2026 |
| BOONE CAPITAL MANAGEMENT LLC | 258K | 0.40% | 0.00% | Jun 2026 |
| Dafna Capital Management LLC | 240K | 0.37% | 0.00% | Jun 2026 |
Adlai Nortye Ltd. American Depositary Shares company profile
- Company name
- Adlai Nortye Ltd. American Depositary Shares
- Ticker
- ANL.US
- Exchange
- USA Stocks
- Listed since
- Sep 29, 2023
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 109
- Fiscal year end
- December
- Address
- 77 Robinson Road, Singapore, Singapore, 068896
- Phone
- 848 230 7430
- Website
- adlainortye.com
About Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (aPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor. The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China. Adlai Nortye Group Ltd. was formerly known as Adlai Nortye Ltd. and changed its name to Adlai Nortye Group Ltd. in July, 2026. Adlai Nortye Group Ltd. was founded in 2004 and is based in Singapore.
Adlai Nortye Ltd. American Depositary Shares management
6- Mr. Yang Lu EMBACo- Founder, CEO & Chairman · born 1979
- Dr. Ngai Chiu Tse M.D., Ph.D.President & Head of Research & Development · born 1967
- Dr. Xiaofeng Ye Ph.D.Chief Financial Officer · born 1979
- Dr. Zhiyong Yu Ph.D.Vice President of Operations
- Mr. Christopher Liu Pharm.D.Head of Investor Relations & Public Relations
- Dr. Nanhai He Ph.D.Head of Discovery